Author
Listed:
- Wadia S. Alruqayb
(University of Birmingham
Taif University)
- Malcolm J. Price
(University of Birmingham
University Hospitals Birmingham NHS Foundation Trust and University of Birmingham)
- Vibhu Paudyal
(University of Birmingham)
- Anthony R. Cox
(University of Birmingham)
Abstract
Introduction Globally, chronic kidney disease (CKD) is one of the leading causes of mortality. Impaired renal function makes CKD patients vulnerable to drug-related problems (DRPs). Aim The aim of this systematic review was to investigate the prevalence and nature of DRPs among hospital in-patients with CKD. Methods A systematic review of the literature was conducted using Medline, EMBASE, PsycINFO, Web of Science (Core Collection), CINAHL plus (EBSCO), Cochrane Library (Wiley), Scopus (ELSEVIER) and PubMed (U.S.NLM) from index inception to January 2020. Studies investigating DRPs in hospitalised CKD patients published in the English language were included. Two independent reviewers extracted the data and undertook quality assessment using the Joanna Briggs Institute (JBI) tool. Results A total of 2895 unique titles were identified; with 20 meeting the inclusion criteria. DRPs prevalence in CKD was reported between 12 and 87%. The most common DRPs included ineffective treatment, inappropriate drug choice and dosing problems. Antibiotics, H2-antihistamines and oral antidiabetics (metformin) were common drug classes involved in DRPs. Factors associated with DRPs included severity of CKD, the number of medications taken, age, length of hospital stay, and gender. Conclusion This systematic review provides evidence that DRPs are a frequent occurrence and burden for hospitalised patients with stage 1–4 CKD. Heterogeneity in study design, case detection and definitions are common, and future studies should use clearer definitions and study designs. Protocol Registration: PROSPERO: CRD42018096364
Suggested Citation
Wadia S. Alruqayb & Malcolm J. Price & Vibhu Paudyal & Anthony R. Cox, 2021.
"Drug-Related Problems in Hospitalised Patients with Chronic Kidney Disease: A Systematic Review,"
Drug Safety, Springer, vol. 44(10), pages 1041-1058, October.
Handle:
RePEc:spr:drugsa:v:44:y:2021:i:10:d:10.1007_s40264-021-01099-3
DOI: 10.1007/s40264-021-01099-3
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:44:y:2021:i:10:d:10.1007_s40264-021-01099-3. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.